

2nd International Conference on Flu

October 31-November 02, 2016 San Francisco, USA



Phillip Bertrand Berkey Moheno

SanRx Pharmaceuticals Inc., USA

Calcium folate for flu prevention and control

Calcium folate is the excess calcium salt of the vitamin folic acid. Folic acid is sensitive to acidic-oxidative conditions and in the presence of excess Ca^{+2} as well, is transformed into pterins and calcium pterins. This pilot observational study describes the use of CaFolate-derived calcium pterin 6-carboxylate in the treatment of certain immune-related ailments. Patients with various immune-associated disorders were directed to take ad libitum 25-76 mg of CaFolate (300-900 μg folic acid equivalents) orally per day, as an adjuvant therapy and to collect personal and medical assessments. The users reported no flu/colds (>20/20 reporting none during the cold and flu season), greater energy/stamina (8/8 reporting increased), less osteoarthritis pain (10/11 reporting improvement), diminished mouth sores due to chemotherapy (2/2 reporting significant clearance) and cancer remissions (4/5 reported plus 1 transient improvement in a terminal case). These observational findings identify certain clinical endpoints for future matched group, randomized, double-blind, placebo-controlled clinical trials. One such clinical trial is underway in osteoarthritis.

Biography

Phillip Bertrand Berkey Moheno holds a BS degree and a PhD in Confluent Education from the University of California, Santa Barbara. He has more than 20 years of research experience in the anti-cancer properties of pterins. He has published 12 papers in reputed journals.

phil.moheno@sanrx.com